

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Triglyceride Lowering Agents PDL Edit
<b>First Implementation Date:</b>	December 6, 2006
<b>Proposed Date:</b>	October 17, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** The fibric acid derivatives (fibrates) are designed to lower triglycerides and to raise high-density lipoprotein (HDL). Fibrates have been shown to lower triglycerides by as much as 35-50% and to raise HDL by as much as 15-25%. Omega-3-Fatty Acids are present in fatty fish such as mackerel, lake trout, herring sardines, albacore tuna, and salmon and also in dietary supplements of fish oil concentrates, but large quantities of these products are required to reach therapeutic doses. Lovaza<sup>®</sup> is a highly purified ethyl ester concentrate of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), two kinds of omega-3-fatty acids. The major effect of Lovaza is to lower triglycerides, although the mechanism of action is not entirely understood. These agents should be used in addition to a diet restricted in saturated fat and cholesterol when the individual response has been inadequate.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Fenofibrate 54, 67, 134, 160, 200 mg (gen Lofibra<sup>®</sup>)</li> <li>Fenofibrate 48, 145 mg (gen Tricor<sup>®</sup>)</li> <li>Gemfibrozil</li> </ul>	<ul style="list-style-type: none"> <li>Antara<sup>®</sup></li> <li>Fenofibrate (gen Antara<sup>®</sup>)</li> <li>Fenofibrate (gen Fenoglide<sup>®</sup>)</li> <li>Fenofibrate (gen Lipofen<sup>®</sup>)</li> <li>Fenofibrate (gen Triglide<sup>®</sup>)</li> <li>Fenofibric Acid (gen Fibracor<sup>®</sup>)</li> <li>Fenofibric Acid (gen Trilipix<sup>®</sup>)</li> <li>Fenoglide<sup>®</sup></li> <li>Fibracor<sup>®</sup></li> <li>Icosapent ethyl (gen Vascepa<sup>®</sup>)</li> <li>Lipofen<sup>®</sup></li> <li>Lopid<sup>®</sup></li> <li>Lovaza<sup>®</sup></li> <li>Omega-3 Acid Ethyl Esters</li> <li>Tricor<sup>®</sup></li> <li>Triglide<sup>®</sup></li> <li>Trilipix<sup>®</sup></li> <li>Vascepa<sup>®</sup></li> </ul>

Type of Criteria:  Increased risk of ADE  
 Appropriate Indications

Preferred Drug List  
 Clinical Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Triglyceride Lowering Agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents **OR**
  - For Lovaza or Vascepa therapy: Triglyceride levels  $\geq$  500 mg/dL allow first line therapy access

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:

<input checked="" type="checkbox"/>
<input type="checkbox"/>

Progress Notes:  
Other:

<input type="checkbox"/>
<input type="checkbox"/>

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

- Evidence-Based Medicine Analysis: "Triglyceride Lowering Agents", UMKC-DIC; April 2023.
- Evidence-Based Medicine and Fiscal Analysis: "Triglyceride Lowering Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- Grundy S, Stone N, Bailey A, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 June, 73(24) e285-e350.
- Virani SS, Morris PB, et. al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia. J Am Coll Cardiol. 2021 June, 78(9). 960-993.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.

*SmartPA PDL Proposal Form*

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.